AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7493372 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 million units daily for 14 days)
Number of subjects: 0
Study 7493372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFN-alpha treatment)
Number of subjects: 0
Study 7493372 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 0
Study 2097909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzocaine 20%
Number of subjects: 0
Study 2097909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 5%
Number of subjects: 0
Study 2097909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2097909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzocaine 20% vs Topical lidocaine 5%
Number of subjects: 0
Study 2097909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetics (benzocaine 20% and lidocaine 5%)
Number of subjects: 0
Study 6162314 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) treatment
Number of subjects: 30
Study 6162314 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study 30807516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 0.5‐mg ranibizumab
Number of subjects: 25
Study 30807516 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 25
Study 28800951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration contrast media (HCCM) injection protocol with low tube current (effective mAs reduced by a factor of 0.6, HCCM 400 mgI/mL)
Number of subjects: 81
Study 28800951 — intervention group
Group type: COMPARATOR
Intervention: Low concentration contrast medium (300 mgI/mL) with automatic mAs
Number of subjects: 81
Study 26059274 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin/carboplatin (Arm A)
Number of subjects: 88
Study 26059274 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (Arm B)
Number of subjects: 88
Study 26059274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 23787155 — intervention group
Group type: EXPERIMENTAL
Intervention: High Hb group (target Hb 11.0 ≤ target Hb ≤ 13.0 g/dL with darbepoetin alfa)
Number of subjects: 206
Study 23787155 — intervention group
Group type: COMPARATOR
Intervention: Low Hb group (target Hb 9.0 ≤ target Hb ≤ 11.0 g/dL with recombinant human erythropoietin)
Number of subjects: 206
Study 23787155 — intervention group
Group type: EXPERIMENTAL
Intervention: High Hb group
Number of subjects: 206
Study 21636031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (switch group)
Number of subjects: 2357
Study 21636031 — intervention group
Group type: COMPARATOR
Intervention: UFH plus glycoprotein IIb/IIIa inhibitor (control group)
Number of subjects: 2357
Study 19855038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention by trained family physicians
Number of subjects: 65
Study 19855038 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 65
Study 16540812 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 264
Study 16540812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 14743544 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (Vit E group)
Number of subjects: 83
Study 14743544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 10877738 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine
Number of subjects: 33
Study 8888297 — intervention group
Group type: EXPERIMENTAL
Intervention: Body tilted 45 degrees
Number of subjects: 0
Study 8888297 — intervention group
Group type: COMPARATOR
Intervention: Body erect
Number of subjects: 0
Study 8888297 — intervention group
Group type: EXPERIMENTAL
Intervention: Body tilted 45 degrees after extensive practice
Number of subjects: 0
Study 1544739 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg caffeine with exercise (running for 30 min at 75% of maximum heart rate)
Number of subjects: 9
Study 1544739 — intervention group
Group type: COMPARATOR
Intervention: 450 mg caffeine without exercise
Number of subjects: 9
Study 3916264 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine fading
Number of subjects: 27
Study 3916264 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine fading plus relaxation
Number of subjects: 27
Study 3916264 — intervention group
Group type: COMPARATOR
Intervention: Self-initiated treatment
Number of subjects: 27
Study 30272459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed letter incorporating principles of motivational interviewing and addressing outcome expectancies plus a telephone reminder call
Number of subjects: 69
Study 30272459 — intervention group
Group type: COMPARATOR
Intervention: Telephone reminder call only
Number of subjects: 69
Study 29756790 — intervention group
Group type: EXPERIMENTAL
Intervention: PATd/TAU
Number of subjects: 79
Study 29756790 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 79
Study 27312538 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT) cream containing oestradiol 50mcg and norethisterone acetate 140mcg
Number of subjects: 116
Study 27312538 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention exercise
Number of subjects: 116
Study 27312538 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 116
Study 27312538 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 116
Study 26321237 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP-guided PVI
Number of subjects: 2113
Study 26321237 — intervention group
Group type: COMPARATOR
Intervention: Conventional PVI
Number of subjects: 2113
Study 23493565 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy training on a validated colonoscopy simulator protocol
Number of subjects: 30
Study 23493565 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy training on a validated laparoscopy simulator curriculum
Number of subjects: 30
Study 23493565 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 30
Study 21874637 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 100
Study 21874637 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 100
Study 19170463 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg, fixed‐flexible dose)
Number of subjects: 159
Study 19170463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 16791541 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily modified-release MPH (EqXL) at doses of 20, 40, or 60 mg
Number of subjects: 0
Study 16791541 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily immediate-release methylphenidate (MPH-IR) at doses of 10, 20, or 30 mg
Number of subjects: 0
Study 16791541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15531675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d)
Number of subjects: 16
Study 15531675 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg/d)
Number of subjects: 16
Study 15531675 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 16
Study 10834775 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.25% with epinephrine (20 microg/h)
Number of subjects: 28
Study 10834775 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.25% without epinephrine
Number of subjects: 28
Study 10834775 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine with epinephrine
Number of subjects: 28
Study 9314869 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug regimen (doxorubicin 25 mg/m2 on days 1-3 and cisplatin 100 mg/m2 on day 1 for six cycles over 18 weeks)
Number of subjects: 407
Study 9314869 — intervention group
Group type: COMPARATOR
Intervention: Multi-drug regimen (preoperatively vincristine, high-dose methotrexate, and doxorubicin; postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, and cisplatin over 44 weeks)
Number of subjects: 407
Study 7984314 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% isoflurane in air (group 1)
Number of subjects: 51
Study 7984314 — intervention group
Group type: COMPARATOR
Intervention: 3% isoflurane and 60% N2O (group 2)
Number of subjects: 51
Study 7984314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 2566790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus melarsoprol
Number of subjects: 598
Study 2566790 — intervention group
Group type: COMPARATOR
Intervention: Melarsoprol only
Number of subjects: 598
Study 1824 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg d-amphetamine
Number of subjects: 9
Study 1824 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg d-amphetamine with lithium carbonate
Number of subjects: 9
Study 1824 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg l-amphetamine with lithium carbonate
Number of subjects: 9
Study 31335733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical power
Number of subjects: 95
Study 31335733 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐β1
Number of subjects: 95
Study 31335733 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF
Number of subjects: 95
Study 28482692 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate (per 5 bpm increase)
Number of subjects: 2705
Study 28482692 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate (per 5 bpm increase) without β-blockers
Number of subjects: 2705
Study 25845224 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-injection of BCG polysaccharide nucleic acid
Number of subjects: 60
Study 25845224 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular-injection of BCG polysaccharide nucleic acid
Number of subjects: 60
Study 25831701 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of washed erythrocytes from placental/umbilical cord blood
Number of subjects: 122
Study 25831701 — intervention group
Group type: COMPARATOR
Intervention: Donor erythrocytes
Number of subjects: 122
Study 22459649 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric Modulated Arc Therapy (RapidArc)
Number of subjects: 20
Study 22459649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic IMRT (d-IMRT)
Number of subjects: 20
Study 22459649 — intervention group
Group type: COMPARATOR
Intervention: 3D Conformal Radiotherapy (3D-CRT)
Number of subjects: 20
Study 20718625 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters (self-reported cigarette abstinence confirmed with exhaled carbon monoxide [CO] <or=8 ppm at 3 and 16 months after quit date)
Number of subjects: 119
Study 20718625 — intervention group
Group type: COMPARATOR
Intervention: Continued smokers
Number of subjects: 119
Study 18684382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention after global geriatric assessment (GGA)
Number of subjects: 620
Study 18684382 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 620
Study 18684382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention after GGA
Number of subjects: 620
Study 15526012 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo (300 units per kg per dose, subcutaneous, for 10 days) plus oral iron
Number of subjects: 60
Study 15526012 — intervention group
Group type: COMPARATOR
Intervention: Oral iron alone
Number of subjects: 60
Study 12909493 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament resection
Number of subjects: 180
Study 12909493 — intervention group
Group type: COMPARATOR
Intervention: Conservative surgery
Number of subjects: 180
Study 10563709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 150 mg twice a day
Number of subjects: 10
Study 10563709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg twice a day
Number of subjects: 10
Study 10563709 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 150 mg and 300 mg regimens
Number of subjects: 10
Study 9494257 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetin guacyl (1200 mg/day for first 3 days, then 600 mg/day for remaining 27 days)
Number of subjects: 50
Study 9494257 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (150 mg/day in three daily administrations on a full stomach)
Number of subjects: 50
Study 8372257 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 150
Study 8372257 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole
Number of subjects: 150
Study 8372257 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 150
Study 3787553 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded peak flow meter
Number of subjects: 12
Study 3787553 — intervention group
Group type: COMPARATOR
Intervention: Uncoded peak flow meter
Number of subjects: 12
Study 29301477 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided reverse bevel fine-needle biopsy sampling (EUS-FNB)
Number of subjects: 68
Study 29301477 — intervention group
Group type: COMPARATOR
Intervention: Conventional fine-needle aspiration (EUS-FNA)
Number of subjects: 68
Study 29301477 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA + FNB
Number of subjects: 68
Study 29301477 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNB and EUS-FNA
Number of subjects: 68
Study 26446702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool pad pillow topper (CPPT) + standard care
Number of subjects: 74
Study 26446702 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 74
Study 23877124 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention with an early weight loss programme
Number of subjects: 60
Study 23877124 — intervention group
Group type: COMPARATOR
Intervention: Routine lifestyle counselling
Number of subjects: 60
Study 23877124 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 60
Study 22424397 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program including Spirometry Fundamentals™ CD‐ROM, interactive webinars, and internet-based feedback system
Number of subjects: 36
Study 20060298 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground walking
Number of subjects: 16
Study 20060298 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking while holding a handrail
Number of subjects: 16
Study 20060298 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking without using a handrail
Number of subjects: 16
Study 20060298 — intervention group
Group type: EXPERIMENTAL
Intervention: General recommendation
Number of subjects: 16
Study 18713921 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (5 mg)
Number of subjects: 40
Study 18713921 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (5-15 mg)
Number of subjects: 40
Study 18713921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16132797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood screening
Number of subjects: 2915
Study 16132797 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening sigmoidoscopy
Number of subjects: 2915
Study 16132797 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening colonoscopy
Number of subjects: 2915
Study 16132797 — intervention group
Group type: EXPERIMENTAL
Intervention: Either screening endoscopy (fecal occult blood screening or sigmoidoscopy)
Number of subjects: 2915
Study 12209274 — intervention group
Group type: EXPERIMENTAL
Intervention: PercuTwist technique
Number of subjects: 70
Study 12209274 — intervention group
Group type: COMPARATOR
Intervention: Blue Rhino technique
Number of subjects: 70
Study 10472510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (25 mg) nicotine patch therapy
Number of subjects: 408
Study 10472510 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (15 mg) nicotine patch therapy
Number of subjects: 408
Study 8943121 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repair (within 4 hours of admission)
Number of subjects: 54
Study 8943121 — intervention group
Group type: COMPARATOR
Intervention: Delayed repair (more than 24 hours after birth)
Number of subjects: 54
Study 8117635 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% bupivacaine with epinephrine
Number of subjects: 22
Study 8117635 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 22
Study 3767037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg X kg‐1)
Number of subjects: 8
Study 3767037 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (0.1 mg X kg‐1)
Number of subjects: 8
Study 3767037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30100317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip Closure Training (LCT)
Number of subjects: 20
Study 30100317 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 26472043 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) with loading dose (400 mg Weeks 0/2/4)
Number of subjects: 338
Study 26472043 — intervention group
Group type: COMPARATOR
Intervention: Certolizumab pegol (CZP) without loading dose
Number of subjects: 338
Study 26472043 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) with loading dose
Number of subjects: 338
Study 24798614 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line antiretroviral therapy (efavirenz or nevirapine with zidovudine/lamivudine or tenofovir/lamivudine)
Number of subjects: 650
Study 24798614 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine regimen (less than 1 year)
Number of subjects: 650
Study 24798614 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine regimen (greater than 1 year)
Number of subjects: 650
Study 24798614 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line antiretroviral therapy (in Nigeria)
Number of subjects: 650
Study 24798614 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine regimen (in Nigeria)
Number of subjects: 650
Study 23169985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading followed by 90 mg bid
Number of subjects: 55
Study 23169985 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading followed by 10 mg od
Number of subjects: 55
Study 23169985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 55
Study 23169985 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 55
Study 23169985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Prasugrel
Number of subjects: 55
Study 20448066 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine albumin-creatinine ratio (ACR)
Number of subjects: 1186
Study 20448066 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed urine albumin excretion rate (AER)
Number of subjects: 1186
Study 20448066 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated AER (eAER) derived from ACR
Number of subjects: 1186
Study 20448066 — intervention group
Group type: COMPARATOR
Intervention: DCCT intensive diabetes therapy
Number of subjects: 1186
Study 20448066 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1186
Study 18350462 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary bicycle
Number of subjects: 80
Study 18350462 — intervention group
Group type: COMPARATOR
Intervention: Treadmill
Number of subjects: 80
Study 15699654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 27
Study 16388267 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 gauge Quincke spinal needle
Number of subjects: 60
Study 16388267 — intervention group
Group type: COMPARATOR
Intervention: 26 gauge Eldor spinal needle
Number of subjects: 60
Study 10226872 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (4 x 200 mg/day, p.o.)
Number of subjects: 9
Study 10226872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8709351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen withdrawal with 300 mg cyproterone acetate daily for 12 weeks
Number of subjects: 213
Study 8709351 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 213
Study 8709351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen withdrawal
Number of subjects: 213
Study 1826175 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 111
Study 1826175 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 7336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum‐magnesium hydroxide (AMH)
Number of subjects: 8
Study 7336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CC)
Number of subjects: 8
Study 7336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide‐magnesium trisilicate (AHMT)
Number of subjects: 8
Study 7336470 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin alone
Number of subjects: 8
Study 7336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative urinary 5‐(4‐hydroxyphenyl)‐5‐phenylhydantoin at 72 hr (HPPH72)
Number of subjects: 8
Study 31057021 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 716
Study 31057021 — intervention group
Group type: COMPARATOR
Intervention: No job adjustments
Number of subjects: 716
Study 31057021 — intervention group
Group type: COMPARATOR
Intervention: Any pain in the pelvic girdle
Number of subjects: 716
Study 31057021 — intervention group
Group type: COMPARATOR
Intervention: Anterior pelvic pain
Number of subjects: 716
Study 31057021 — intervention group
Group type: COMPARATOR
Intervention: Posterior pelvic pain
Number of subjects: 716
Study 28646892 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking up the spirit acupuncture
Number of subjects: 60
Study 28646892 — intervention group
Group type: COMPARATOR
Intervention: Hand and foot 12-meridian acupuncture
Number of subjects: 60
Study 26001387 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg single dose)
Number of subjects: 12